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Anthracyclines remain the cornerstone of treatment in many malignancies but these agents have a cumulative dose relationship
with cardiotoxicity. Development of cardiomyopathy and congestive heart failure induced by anthracyclines are typically dose-
dependent, irreversible, and cumulative. Although past studies of cardiotoxicity have focused on anthracyclines, more recently
interest has turned to anticancer drugs that target many proteins kinases, such as tyrosine kinases. An attractive model to explain
the mechanism of this cardiotoxicity could be myocyte loss through cell death pathways. Inhibition of mitochondrial transition
permeability is a valuable tool to prevent doxorubicin-induced cardiotoxicity. In response to anthracycline treatment, activation
of several protein kinases, neuregulin/ErbB2 signaling, and transcriptional factors modify mitochondrial functions that determine
celldeathorsurvivalthroughthemodulationofmitochondrialmembranepermeability.Cellularresponsetoanthracyclinesisalso
modulated by a myriad of transcriptional factors that inﬂuence cell fate. Several novel targeted chemotherapeutic agents have been
associated with a small but worrying risk of left ventricular dysfunction. Agents such as trastuzumab and tyrosine kinase inhibitors
can lead to cardiotoxicity that is fundamentally diﬀerent from that caused by anthracyclines, whereas biological eﬀects converge to
the mitochondria as a critical target.
1.Introduction
Cardiotoxicity is a term often used to describe a broad range
of adverse eﬀects on heart function induced by therapeutic
molecules. These eﬀects may either emerge early in preclin-
ical studies or become apparent latter in the clinical setting
after the drug has already been licensed for clinical use. The
use of several chemotherapeutics for the treatment of cancer
is associated with a risk of cardiovascular complications [1–
3]. They present as a defect in cardiac function that can be
either symptomatic or not. The classic example of this issue
is the use of anthracyclines such as doxorubicin, which is
commonly prescribed to treat hematological malignancies
and solid tumors [4, 5].
Potential cardiovascular toxicities linked to anticancer
drugs include increases of QT duration, arrhythmias,
and myocardial ischemia (antimetabolite compounds) [6],
hypertension and thromboembolic complications (antian-
giogenic agents) [7], and myocardial dysfunction [1]. The
latter, variable in severity, can be reversible or not and can
occur during treatment or later on. For example, the clinical
use of anthracyclines such as doxorubicin is hampered by
the development of cardiomyopathy and congestive heart
failure, which are typically dose-dependent and cumulative.
While acute cardiotoxicity occurs, the most troublesome
form manifests late after treatment and is characterized by
structural changes of the human heart [8], leading to de-
creases in the left ventricle wall thickness and myocardium
mass, as well as reduced ventricular compliance [9]. Unlike
acute toxicity, the delayed manifestation of anthracycline use
often presents as symptomatic heart failure and is considered
largely irreversible [1, 5, 10].
Although past studies of cardiotoxicity have focused
on anthracyclines, more recently interest has turned to2 Biochemistry Research International
anticancer drugs that target many proteins kinases, such
as tyrosine kinases [2]. Targeted therapeutics, particularly
those that inhibit the activity of protein kinases that are mu-
tated and/or overexpressed in cancer, have revolutionized
the treatment of some cancers and improved survival in
many others [11, 12]. Unexpected cardiotoxicity induced by
targeted drugs has been related to the existence of numer-
ous parallels between signaling pathways that drive tumori-
genesis and those that regulate survival of cardiomyocytes
[12–15]. For example, on-target heart toxicity of tras-
tuzumab, a monoclonal antibody against the ErbB2 receptor
[16] revealed that human epidermal growth factor receptor 2
signaling also interfered with survival pathway in cardiomy-
ocyte, a terminally diﬀerentiated cell [16, 17]. At this point,
it can be hypothesized that mitochondrial dysfunction and
ATP depletion arethemain contributorsto targetedtherapy-
induced cardiac toxicity [15].
Anattractivemodeltoexplainthemechanismofthiscar-
diotoxicity could be myocyte loss through cell death path-
ways [18, 19]. Given the limited regenerative capacity of
the heart, cumulative toxicity may be explained by the pro-
gressiveincreaseofcardiaccellloss.Cardiaccellstress(speci-
ﬁcally oxidative stress induced by anthracyclines and many
kinaseinhibitors)activatesapoptosisandnecrosisviaamito-
chondrial pathway [1, 10]. As mitochondria are a central
component of intrinsic apoptotic and necrotic pathways,
mitochondrial “eﬀects” of anticancer drugs are to be an ex-
pectedoutcomeofadverseinteractionsbetweenthedrugand
cells [20].
2. Overview of AnthracyclineCardiotoxicity
2.1. Clinical Picture of Cardiac Toxicity. Anthracycline-in-
duced cardiotoxicity has been categorized into acute, early-
onset chronic progressive and late-onset chronic progressive
forms [21]. Acute cardiotoxicity occurs during or shortly
after drug infusion and includes nonspeciﬁc EKG changes
and arrhythmias, which may be accompanied in some pa-
tients by heart failure and pericarditis-myocarditis syndrome
[9]. These complications are typically reversible, not dose-
dependent and do not preclude further anthracycline use.
Single cases of acute cardiac failure and sudden death were
also reported [9, 22]. The subacute cardiac toxicity occurs
within a few weeks, clinically resembles myocarditis (with
edema and thickening of the left ventricle LV walls), and is
associated with 60% mortality [22]. Acute cardiotoxicity oc-
cur in 1% of patients, whereas the subacute form occurs in
1.4–2% of patients [9]. Clinically the most signiﬁcant eﬀect
of anthracyclines is chronic cardiac toxicity that may lead to
LV dysfunction and congestive heart failure [23, 24]. Late-
onset chronic progressive cardiotoxicity usually appears at
least one year after completion of therapy and manifests
clinically in 1.6–5% of patients [24]. Late-onset chronic pro-
gressive may not become evident until 10 to 20 years after
the ﬁrst dose of cancer treatment. The prognosis in anthra-
cycline-related heart failure is poor, with 50% 2-year mor-
tality in untreated established LV dysfunction [24, 25]. The
most important risk factor for late cardiac toxicity is the cu-
mulative anthracycline dose [25].
It is believed that each anthracycline dose causes struc-
tural changes to cardiomyocytes, which ultimately lead to
cardiomyocyte death. These defects are balanced by com-
pensatorymechanismsuntilacertainthreshold,abovewhich
ventricularremodelingcommontomultipleformsofcardiac
injury is triggered. The estimated risk of chronic heart fail-
ure for doxorubicin dose greater than 400mg/m2 ranges
from 3% to 5%, for 550mg/m2 from 7% to 26%, and for
700mg/m2 from 18% to 48% [1, 10]. In clinical practice,
however, it seems wise to estimate the risk as being in the
upperlimitofthegivenrangesandadaptmaximumcumula-
tive doses accordingly [26]. Despite a considerable variability
in individual dose-response relationship for cardiac toxicity,
the maximum lifetime cumulative dose for doxorubicin is
400 to 550mg/m2 [1, 10]. The long-term follow-up data
of patients treated with adjuvant anthracycline-based regi-
mens demonstrated increased incidence of symptomatic and
asymptomatic left ventricular dysfunction and decrease in
the mean LVEF value, suggesting that the incidence and se-
verity of postanthracycline heart damage increases with time
[26]. Overall, these data stress the importance of cardiac
follow-up well beyond the treatment period.
2.2. Proposed Pathophysiology. Despite a remarkably exten-
sive literature on many aspects of cardiotoxicity, a single
unifying theory for the deleterious eﬀects of anthracyclines
on the heart is still lacking. Anthracycline-induced myocar-
dial damage has long been regarded as occurring primarily
through the generation of reactive oxygen species and free
radicals [27]. This oxidative stress model is supported by
many studies showing ROS formation, especially in the
setting of increased intracellular iron levels, in response to
anthracycline treatment [27, 28]. Recent studies, however,
have suggested that the ROS model is inadequate to account
for all features of anthracycline cardiotoxicity [27]. Indeed,
there is strong evidence that anthracycline cardiotoxicity
stems from (at least partially) ROS-independent mecha-
nisms, such as cardiomyocyte apoptosis or necrosis, disrup-
tion of normal sarcomere structure and altered energetics
impairing the cardiac cell ability to generate adequate co-
ntraction [18, 29–31]. Recent studies have highlighted the
eﬀects of anthracyclines on compensatory prosurvival mech-
anisms, suchasneuregulin/heregulin-Erb/HER2 and cellsal-
vage kinase pathways, which may modulate the development
of heart failure [32, 33]. Figure 1 provides a summary of
thediﬀerentsignalingpathwaysinvolvedinanthracycline-in-
duced cardiotoxicity.
2.3.OxidativeStressPathwayandIronHypothesis. Thechem-
ical structure of anthracyclines is complex: these drugs are
composed of an aglycone and a sugar. The aglycone consists
of a tetracyclic ring with adjacent quinone-hydroquinone
moieties. Quinone moieties have toxicological importance
because of their involvement in both reductive and oxidative
biotransformation leading to highly reactive species involved
in cardiotoxicity [27, 34].
One-electron reduction of the tetracyclic ring of anthra-
cyclines leads to the formation of a semiquinone free radical.
This radical is relatively stable in an anoxic environment,Biochemistry Research International 3
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Figure 1: Potential signaling pathways involved in anthracycline-induced cardiomyocyte injury. Anthracycline-induced cell death is
balanced by intracellular survival signaling which is linked to neuregulin/ErbB2 and Akt activation. The suggested principal mechanism
of anthracycline damage is via generation of reactive oxygen species ROS by iron-anthracycline complexes, leading to lipid peroxidation
and membrane damage. Oxidative stress (ROS, nitric oxide NO, and peroxynitrite ONOO–) causes activation of kinase pathways (mitogen-
activated protein kinase MAPK, stress-activated protein kinase SAPK, c-Jun N-terminal kinases JNK) modulating response to anthracyclines
and linking to apoptotic pathway. In mitochondria, ROS and calcium overload lead to the release of cytochrome c (cyt c) from mitochondria
into cytoplasm, via mitochondrial permeability transition pore opening (mPTP), which results in membrane potential dissipation (delta psi
m), activation of caspases and apoptosis. Other putative mechanisms include damage to nuclear DNA, disruption of sarcomeric protein,
suppression of transcription factors (GATA-4, p300, p53) that regulate cell survival and sarcomeric protein synthesis, and disturbance of
energy metabolism.
but under normoxic conditions, its unpaired electron is do-
nated to oxygen, forming superoxide radicals. Suitable ﬂavo-
proteins such as complex I catalyze the formation of reduced
semiquinone radicals by accepting electrons from NADH
or NADPH and donating them to anthracyclines. This se-
quence of reactions, known as “redox cycling,” can be highly
damaging, because a relatively small amount of drug is suf-
ﬁcient for the formation of numerous superoxide radicals.
The redox cycling of anthracyclines has been described in cy-
toplasm, mitochondria, and sarcoplasmic reticulum [27].
The ﬁrst targets of anthracycline-mediated free-radical dam-
age are various cellular membranes, which are rich in lipids
prone to peroxidation. This radical damage results in pro-
ductionofmanystableandhighlytoxicaldehydes,whichfur-
ther attack macromolecular targets. Although formation of
ROSisinducedbythequinonemoietyofanthracyclines,oxi-
dative stress can also occur via induction of nitric oxide syn-
thase, leading to superoxide anion, nitric oxide and perox-
ynitrite formation [18, 27].
Promotion of myocardial oxidative stress remains by far
the most frequently proposed mechanisms of anthracycline-
induced cardiotoxicity [27]. Production of ROS that follows
nuclear binding of the drug results in injuries to DNA as
well as to cell membranes and mitochondria. ROS produc-
tion is involved in a vast variety of cardiotoxicity inducing
mechanisms, including impaired expression of cardiac pro-
teins, disruption of cellular and mitochondrial calcium ho-
meostasis, induction of mitochondrial DNA lesions, dis-
ruption of mitochondrial bioenergetics and ATP transfer
systems, and degradation of myoﬁlament and cytoskeleton
proteins [18, 29–31]. Involvement of oxidative stress in
the pathogenesis of anthracycline cardiotoxicity has been
supportedbyseveralapproaches,thatis,isolatedcardiaccells
displaying perimitochondrial ROS production in response to
anthracycline exposition, cultured cell and animal models
showing that antioxidant prevented anthracycline-induced
cardiotoxicity, and resistance of transgenic mice overexpress-
ing the mitochondrial manganese-superoxide dismutase to
anthracycline-induced cardiotoxicity [35].
Anthracyclines may promote the formation of ROS
through redox cycling of their aglycones as well as their
anthracycline-iron complexes. Indeed, unless adequately se-
questered within the cells, iron can dramatically promote
ROS production by the Fenton and Haber-Weiss reactions
and the formation of reactive anthracycline-iron complexes
[27, 34]. Cellular iron (Fe) level is tightly regulated by the4 Biochemistry Research International
transferring receptor and storage regulating ferritin, both of
which are, themselves regulated at the posttranscriptional
level by interactions of Fe-regulatory-protein (IRP-1) with
speciﬁc motifs iron-responsive-elements (IREs) in target
genes. Doxorubicin and its metabolites can disrupt the Fe-
S cluster of cytoplasmic aconitase and inhibit IRP-1. In do-
xorubicin-treated cardiomyocytes, increased IRP-1 inhibi-
tion leads to intracellular Fe accumulation causing increased
oxidative stress [36].
Consistent results suggesting the involvement of oxida-
tiveandnitrosativeoxidantstressesinanthracycline-induced
cardiotoxicity provide a rationale for cardioprotection with
antioxidantsinhumans[27,37].Unfortunately,useofdiﬀer-
ent antioxidant agents have failed to provide protection in
both preclinical experiments and clinical studies [3]. First
generation antioxidant molecules such as N-acetylcystein,
vitamins D, E have been investigated on the basis of some
protective eﬀects observed in animal models [27]. None of
these antioxidant approaches has yet shown consistent eﬃ-
ciency. The only compound found to reduce long-term car-
diac dysfunction is dexrazoxane, although whether its eﬃ-
ciency is related to its antioxidant properties or other mech-
anisms remains under debate [3]. For example, underlying
mechanismsof dexrazoxaneinclude prevention ofiron accu-
mulation, which is implicated in increased ROS production
and anthracycline-induced cardiotoxicity.
2.4. Mitochondrial Apoptosis and Necrosis Pathway. Cardiac
side eﬀects of anthracyclines involve two main mechanisms,
whichinteractwitheachother,oxidative stressandapoptosis
[18, 27]. Most of the cellular events induced by ROS genera-
tion contribute to cardiomyocyte death, which has been
showntobeaprimarymechanismforanthracycline-induced
cardiomyopathy.Indeed,cardiacmyocytelossfollowingacti-
vation of both apoptotic and necrotic pathways provide an
attractive explanation for anthracycline-induced cardiotoxi-
city [18, 20, 38]. Studies in animals have demonstrated that
apoptotic cell death occurs after in vivo exposure to anthra-
cyclines[38].Experimentalcellcultureshavealsoshownthat
anthracyclines induce both apoptotic and necrotic cell death
[38]. Evidence of mitochondrial injuries and hallmarks of
apoptosis have been found in endomyocardial biopsies of
patients treated with anthracyclines [8, 39]. Overall, cardiac
myocyte death following anthracycline administration typi-
cally presents with biochemical features of apoptosis and the
morphological aspect of cell necrosis [18, 20, 38].
Anthracycline-induced apoptosis in the heart appears to
involve a mitochondrial pathway, which requires Bax, cyto-
chrome c and caspase-3 [20]. Typically, anthracycline treat-
ment increases mitochondrial oxidative stress and disrupts
intracellular calcium levels [40, 41]. Increased intracellular
calcium, favored by calcium ﬂux aberrations, eventually
raises mitochondrial calcium levels. Above a certain thresh-
old, this calcium overload triggers permeability transition of
the mitochondria, resulting in the dissipation of transmem-
brane potential, as well as mitochondrial swelling and in-
creased permeability of its outer membrane to apoptotic fac-
tors such as cytochrome c [20]. In the cytosol, cytochrome c
forms a complex with the adaptor protein apoptosis protease
activator protein-1 (Apaf-1), dATP, and caspase-9, so-called
apoptosome, which in turn activates caspase-9. The intrinsic
pathway converges then to the downstream executioner
caspases [20].
The current hypothesis is that necrotic and some forms
of apoptotic cell death involve prolonged opening of a large
conductance pore in the mitochondria, known as the mito-
chondrial permeability transition pore mPTP [36]. In its
fully open state, the mPTP has been reported to allow un-
restrictedmovementofsolutesof<1.5kDa.Theactivationof
themPTPinisolatedmitochondriahasbeenshowntoleadto
mitochondrial swelling, which is commonly used as an assay
for mPTP opening. In spite of the great recent interest con-
cerning mPTP and its apparent importance in cell death, its
molecular identity is unknown. It has been proposed that
the mPTP is formed through conformational change in the
association of the adenine nucleotide translocator (ANT)
with the voltage dependent anion channel (VDAC) contact
sites between the inner and outer mitochondrial membranes
[42, 43]. Cyclophilin D is thought to regulate the opening
of the pore via its interactions with ANT. These interactions
are inhibited by cyclosporine A supporting the idea that
cyclophilin D play a role in pore opening [42, 43]. Recent
studies have shown that genetic ablation of either ANT or
VDAC isoforms did not result in the absence of mPTP,
suggesting that neither of these proteins is an obligatory
component [43]. In contrat, ablation of cyclophilin D
reduces ischemia-reperfusion-induced cell death, suggesting
aroleforcyclophilininthemPTP[44,45].Growingevidence
suggests that the phosphate carrier is a critical component of
the mPTP and that interaction between ANT and the phos-
phate carrier can modulate mPTP opening [45].
For many years, it has been put forward that the mPTP
contributed mainly to apoptotic cell death as a protagonist of
mitochondrial permeabilization. Recent data suggests, how-
ever, that an increase in mitochondrial membrane perme-
abilization is one of the key events in both apoptotic and
necrotic cell death [43, 44]. This information is important
since necrosis occurs in many forms of adult human heart
injuries,includingthecardiotoxiceﬀectsofanticancerdrugs.
Indeed, in the mid-2000s, new experimental studies suggest-
edthatmPTPdidnotinitiateapoptosisandthatthiscomplex
instead played a central role in necrosis, especially in the
heart. In this line of reasoning, it has been shown that cy-
closporine A (CsA), a known inhibitor of the mPTP, can re-
duce the occurrence of cardiac and brain cell necrosis dur-
ing ischemia reperfusion injury. Studies of cyclophilin-D-de-
ﬁcient mice have also provided consistent evidence that the
m P T Pp l a y sac r u c i a lr o l ei nc e l ln e c r o s i s[ 46, 47]. In these
mice, mPTP was still functional but cyclophilin-D ablation
increasedtheamountofcalciumrequiredformPTPopening
and abolished the sensitivity to CsA [46, 48]. Cyclophilin-
D-deﬁcient mice had increased resistance against necrotic
stimuli such as calcium overload, whereas these animals still
diedinresponsetotreatmentswithclassicalapoptoticinduc-
ers such as staurosporine or etoposide. Overall, this data in-
dicates that mPTP opening is chieﬂy involved in cardiac cell
necrosis rather than in triggering cytochrome c release dur-
ing early apoptosis.Biochemistry Research International 5
2.5. Alternative Types of Cell Death: Oncosis and Autophagy.
Features of cell oncosis, which is typically associated in car-
diomyocytes with mitochondrial and cytoplasmic swelling,
coagulated sarcomere and early rupture of the plasma mem-
brane [49] have been described in anthracycline-induced
cardiac cell damage [50]. As mentioned above, recent studies
have shown that this form of cell death can be well con-
trolled and programmed through mPTP-dependent mech-
anisms. The rationale is that increased ROS leads to mito-
chondrial calcium overloading, promotes mPTP opening,
causes mitochondrial swelling and ATP depletion, and hence
triggers necrotic cell death [20]. Autophagy has evolved as a
conserving process that uses bulk degradation and recycling
of cytoplasmic components, such as long-lived proteins and
organelles. In the heart, autophagy is important for the turn-
over of organelles at low basal levels under normal condi-
tions and it is upregulated in response to stresses such as
ischemia/reperfusion and in cardiovascular diseases such as
heart failure. Recent evidence suggests that autophagic cell
death may play a signiﬁcant role in the myocardial dys-
function induced by doxorubicin [51]. Overall, it could be
statedthatinanthracyclincardiotoxicity,mitochondriaisthe
crossroad for apoptosis, necrosis and autophagy processes,
which may converge in dying cells in response to diﬀerent
pathways including ROS production, calcium overload, and
DNA lesions.
3.Mitochondria-Related
Survival/DeathPathways
If apoptotic and necrotic cell death are central to the feature
of anthracycline-induced cardiotoxicity, then the underlying
mechanisms in play are worth exploring, as they may lead
to cytoprotective strategies. Likewise, better understanding
of activation of cell survival pathways in response to anthra-
cycline exposition may also provide valuable knowledge that
would help in the development of new cytoprotective stra-
tegies.
3.1. Mitochondrial Permeability Transition. Bioenergetic fail-
ure, enzyme inhibitions, lipid peroxidations, induction of
membrane disorders as well as the initiation of oxidative
stress are being attributed to the accumulation of anthracy-
clines at or inside mitochondria. From heart tissue perfused
with anthracyclines two distinct cellular sites of drug accu-
mulation were the nuclei and mitochondria, which become
labeled with the drug [52, 53]. Hence, it has been commonly
proposed that deleterious signals related to anthracycline ex-
posure converge to the mitochondria to favormPTP-mediat-
ed cell death [54]. In addition, if this hypothesis is correct,
an understanding cardioprotective mechanisms is intimately
linked to an understanding of the mechanisms by which mi-
tochondria regulate cell death.
Disruption of mitochondrial calcium homeostasis fol-
lowing chronic doxorubicin administration can be demon-
strated by using cardiac mitochondria isolated from doxo-
rubicin-treated animals [40, 41]. For example, activation of
the selective cyclosporine- (CsA-)sensitive calcium channel
of cardiac mitochondria by doxorubicin occurs both in vitro
[55] and in cardiac mitochondria isolated in rats having un-
dergone chronic in vivo treatment with doxorubicin [56]. In
the latter protocol of exposition (2mg/kg/week doxorubicin
treatment for 13 weeks), isolated mitochondria have a lower
respiratory control ratio and exhibit an enhanced CsA-sen-
sitive release of mitochondrial calcium. Associated with this
was a calcium-induced loss of membrane potential, which
may be inhibited by either cyclosporine A or ruthenium
red. Further experiments have demonstrated that doxoru-
bicin treatment in vivo causes a dose-dependent and irre-
versible interference of mitochondrial calcium transport
and calcium-dependent regulation of membrane potential
indicative of an induction of the mPTP and of an increased
sensitivity to calcium-induced loss of cell viability [57, 58].
ImplicationofthemPTPinthecardiotoxicityofdoxorubicin
has been explored in cyclophilin-D-deﬁcient mice, cyclo-
philin-D being a mitochondrial matrix peptidyl-prolyl iso-
merase known to modulated mitochondrial transition pore
opening. The result that cyclophilin-D deﬁciency in mice
inhibited doxorubicin-induced cardiomyocyte necrosis and
heart failure suggests that mPTP is involved in doxorubicin-
induced cardiotoxicity [48]. This contention is also support-
ed by animal studies showing prevention of doxorubicin
cardiotoxicity by in vivo CsA or FK506 treatment [59, 60].
In human atrial trabeculae, our group also demonstrated
that cyclosporine A prevented doxorubicin-induced mito-
chondrialdysfunctionandimpairedcontractileperformance
induced by doxorubicin [61]. These ﬁndings reinforce the
rationale that mPTP is involved in the development of do-
xorubicin cardiotoxicity in the human myocardium.
3.2. Survival Protein Kinase Signaling. Accumulating evi-
dence indicates that several protein kinases (i.e., Akt, PKCs,
EKR, GSK-3b, hexokinase) receive extra mitochondrial sig-
nals and modify mitochondrial proteins that determine cell
death or survival, such as the mPTP [62]. Activities of
some of these kinases are mutually regulated, and phospho-
rylation of GSK-3β and hexokinase in mitochondria appears
to directly modify the mPTP, elevating its opening threshold
[62]. Doxorubicin may induce inhibition of Akt phospho-
rylation, which increases active glycogen synthase kinase-
3b (GSK-3b) [63]. GSK-3b is a protein kinase linked to
the regulation of a variety of cellular functions within the
myocardium, including glycogen metabolism, gene expres-
sion and cellular survival [62]. GSK-3b phosphorylation,
and, therefore inhibition, could confer cardioprotection
through its potential mitochondrial eﬀects on the mPTP.
Strategies that prevent GSK-3b activation via upstream
kinase activation have been shown to be protective against
doxorubicin treatment. For example, pretreatment with var-
ioustherapeuticmolecules(erythropoietin,thrombopoietin,
CO/HO1) can protect the myocardium against doxorubicin-
induced impaired heart function and cardiomyocyte apop-
tosis by activating Pi3k-Akt cell survival pathways [63–65].
In contrast, upregulation of Ser/Thr phosphatase PP1 by
doxorubicin may be involved in the Akt dephosphorylation,
resulting in executioner caspase activation and cell death
[66].6 Biochemistry Research International
Cellular stress and speciﬁcally oxidative stress has been
shown to activate mitogen/stress activated protein kinases
(MAPKs and SAPKs) that appear to be important in
determiningcellfate.MAPKsandSAPKspathwaysmodulate
the response of the heart to anthracycline exposure [67]a n d
havealsobeenproposedascellularmediatorslinkinganthra-
cyclines to the apoptotic cell death pathway [18, 30]. Under
treatment with anthracyclines that signiﬁcantly induces
myocyteapoptosisintheprimaryculturesofneonatalmouse
cardiomyocytes, p38 MAPK is dramatically activated. That
p38 MAPK may be involved at least in part in the anthra-
cycline-induced myocyte apoptosis is demonstrated by
two important observations. First, the time-course analysis
revealed that p38 MAPK activation typically precedes the
onset of apoptosis. Second, application of inhibitors of p38
MAPK signiﬁcantly inhibits anthracycline-induced myocyte
apoptosis [68]. Although most studies have focused on
the ERK member of the MAPKs, other members of the
MAPKs/SAPKs family have been associated with cardiopro-
tection through the modulation of the mPTP. For example,
JNK and p38 are activated by doxorubicin and linked mPTP
tocardiacmyocyteapoptosis[69].Strategiesreducingactiva-
tion of the MPAKs/SAPKs pathways are typically protective
against doxorubicin cardiotoxicity.
3.3. Genomic Analyses and Cellular Energetic Deﬁcits. Dox-
orubicin typically causes selective downregulation of many
nuclear genes that encode for proteins with mitochondrial
function [70, 71]. The depressive eﬀect on the expression of
genesthatcomprisethemitochondrialproteomeispersistent
and canbe observed weeks afterprolonged administration of
doxorubicin [70]. Previous studies suggest that a prominent
feature of doxorubicin-induced cardiotoxicity is a profound
alteration in the abundance of transcripts related to energy
metabolismandmitochondrialperformance.Consistentevi-
dence suggests that cellular energy deﬁcits related to decrease
in fatty acid and glucose oxidation could play a critical
role in the development of the cardiomyopathy induced by
anthracyclines [29]. For example, oxidation of the long-
chain fatty acid palmitate is inhibited by doxorubicin within
minutes in isolated cardiomyocyte preparation, as well as
in chronic situation in which cardiomyocytes are isolated
from doxorubicin-treated rats. In these studies, impairment
of carnitine palmitoyl transferase I and depletion of its sub-
strate l-carnitine by doxorubicin was demonstrated [72].
Reduction in fatty acid oxidation is not accompanied by up-
regulation of glucose utilization as a compensatory response
[73]. Rather, doxorubicin-induced cardiomyopathy is asso-
ciated with a decreased utilization of both fatty acids and
glucose substrates, which has been related to the eﬀects of
doxorubicin on cellular glucose supply [74] and the impair-
ment of phosphofructokinase, the rate-limiting enzyme of
glycolysis [75].
Furthermore, the selective eﬀects of doxorubicin on sup-
pression of mitochondria gene expression is accompanied by
a coordinate and adaptive response of energy-sensing mole-
cules [76], such as AMP-activated protein kinase (AMPK),
hypoxia-inducible factor 1 (HIF1), nuclear respiratory
factors (Nrf) and proliferator-activated receptor gamma
coactivator1 (PGC1) [77]. Proteomic analyses revealed con-
sistent changes in proteins involved in mitochondria energy
production, energy channeling and mitochondrial antioxi-
dant protection [78, 79]. Overall, this information is in line
with doxorubicin-induced mitochondrial defects at diﬀerent
stages of cardiac energy metabolism, including reduction of
oxidative capacity, changes in the proﬁle of energy substrate
utilization, disruption of energy transfer systems such as
mitochondrial CK, and AMPK-dependent energy signaling
pathways.
3.4. Anthracyclines Induce Sarcomere Functional and Struc-
tural Changes. Functional and structural changes to car-
diomyocyte sarcomeres have been observed in both exper-
imental experiments and in endomyocardial biopsies of pa-
tientstreatedwithanthracyclines.Lossofmyoﬁbrils,disarray
of myoﬁbrils, swelling of mitochondria and dilation of the
sarcoplasmic reticulum were observed [80, 81]. Breakdown
of sarcomeres typically involved early-onset degradation of
the giant myoﬁlament protein, titin. As titin maintains sar-
comere integrity, its accelerated degradation via calpain pro-
teolytic activity in response to doxorubicin can rapidly lead
to sarcomere disorganization and progressive cardiomyocyte
contractile dysfunction [82].
Several lines of evidence indicate that an abnormal cal-
cium handling of myocardial cells may explain, at least in
part, the cardiac dysfunction seen in doxorubicin-induced
cardiomyopathy. For example, doxorubicin has been shown
to inhibit the gene transcription of the sarcoplasmic retic-
ulum Ca2+-ATPase [83] and to activate cardiac calcium
release channels (ryanodine receptors) [84] .Ad e c r e a s eo f
sarcoplasmic reticulum calcium load and hence calcium-in-
duced calcium release has been observed with doxorubicin
in isolated guinea pig ventricular myocytes [85]. The mech-
anism by which doxorubicin aﬀects calcium homeostasis of
cardiac myocytes has not been fully deﬁned but may involve
an iron-catalyzed direct eﬀect of doxorubicin, doxorubicin-
induced formation of reactive oxygen intermediates [83],
and conversion of doxorubicin to the toxic alcohol metabo-
lites [86].
3.5. Transcriptional Factors. Several lines of evidence suggest
that progressive anthracycline-induced cardiac injury results
from eﬀects on myocyte diﬀerentiation programs thereby
impeding myocyte survival and the cardiac adaptative
response. Genes with anthracycline inhibited expression in-
clude genes encoding, transcriptional factors [71, 73]. For
example, anthracyclines can disrupt expression and activity
of the transcription factor GATA-4 [87]. Transcriptional
factor GATA-4 is a member of a zinc ﬁnger transcriptional
factorfamilythatis critical forregulating diﬀerentiation, sar-
comeresynthesisandsurvivalsignaling.GATA-4isexpressed
in the heart and regulates several speciﬁc cardiac genes,
including antiapoptotic genes, making it a key regulator
of heart development. This important survival factor is
rapidly depleted in response to doxorubicin treatment [64,
88]. Anthracyclines downregulate GATA-4 expression in
cardiac myocytes and upregulation of GATA-4 can suppress
doxorubicin-induced myocyte apoptosis and drug-inducedBiochemistry Research International 7
cardiotoxicity [88, 89]. These prosurvival eﬀects have been
linked to the eﬀects of GATA-4 on the upstream activator
of the antiapoptotic gene Bcl-Xl. Since the overexpression of
GATA-4 can attenuate the incidence of apoptosis induced by
anthracyclines, GATA-4 may serve as an antiapoptotic factor
in the heart. Moreover, GATA-4 also regulates expression of
several cardiac speciﬁc genes that are involved in sarcomere
synthesis, such as cardiac troponin C and I and myosin light
chain-3 [90]. Hence, one potential mechanism by which
anthracycline may induced myocardial dysfunction is via
suppression of sarcomere protein expression and sarcopenia
in response to GATA-4 reduction [91].
In addition to GATA-4, the cardiac ankyrin repeat pro-
tein transcriptional regulator CARP and the transcriptional
coactivating factor p300 have been implicated in the car-
diotoxicity of anthracyclines. CARP is rapidly degraded in
myocytes after anthracycline exposure [91, 92]. Suppression
of CARP expression using short-interference RNA is suﬃ-
cient to induce myoﬁbrillar disarray and cell dysfunction
[93]. Similar to CARP, p300 is degraded after doxorubicin
exposure through p38 kinases alpha and beta and is as-
sociated with apoptosis in neonatal cardiomyocytes [93, 94].
In these experiments, restoration of p300 inhibited doxo-
rubicin-induced cell death.
Doxorubicin treatment has been associated with in-
creased expression and activation of p53 tumor suppressor
protein, which activates the intrinsic mitochondrial apopto-
tic pathway [95]. Consistently, p53-knockout mice and adult
mouse hearts expressing cardiac myocyte-restricted domin-
ant-interfering p53 are partially protected against doxo-
rubicin-induced cell death and myocardial dysfunction [96].
In addition, activation of p53 may also mediate anthra-
cycline-induced cardiotoxicity through other pathways inde-
pendentofcardiomyocyteapoptosis.Forexample,p53-med-
iated inhibition of mammalian target of rapamycin signaling
(mTOR) may contribute to the cardiac mass reduction and
myocardial dysfunction observed in doxorubicin-treated
mice [96]. Hence, acute doxorubicin-induced toxicity could
result from p53-dependent modulation of mTOR activity. It
may be thus of considerable interest to determine whether
upstream eﬀectors that activate mTOR pathway would be
cardioprotective against doxorubicin-induced cardiac toxi-
city.
3.6. Neuregulin/ErbB2 Cardioprotective Program. Unexpect-
ed cardiac side eﬀect of ErbB2 antagonists, such as tras-
tuzumab, has sparked great scientiﬁc eﬀorts to elucidate the
role of Neuregulin/ErbB2 pathway in cardiomyocyte func-
tional and structural integrity [16, 17, 97]. Before this obser-
vation, ErbB2 signaling was only recognized as being indis-
pensable to normal fetal cardiac development. Subsequent
studies have demonstrated that stimulation of the ErbB2
signaling by ErbB-receptor ligands improves cardiomyocyte
function and survival in the heart [97].
The ﬁrst evidence regarding the protective eﬀects of
the ErbB2 signaling in the adult heart came from clinical
trials in breast cancer patients using trastuzumab, a mon-
oclonal antibody that blocks the ErbB2 receptor [1, 2].
The incidence of clinical heart failure increased ﬁve-fold in
patients treated concurrently with chemotherapy drug doxo-
rubicin and trastuzumab compared to those treated with
doxorubicin alone [1]. Mostly based on the analogy between
ErbB2knockout-inducedcardiomyopathyandtrastuzumab-
induced heart failure, many studies have concluded that
trastuzumab causes heart failure by blocking the physiolog-
ical actions of ErbB2 in the heart [32, 33]. The synergistic
increase of heart failure incidence has been related to the
fact that ErbB2 expression is upregulated following doxo-
rubicin administration, while trastuzumab inhibits the
ErbB2 downstream pathways, which is essential for cell re-
pair,survival,andfunction.Thus,iftrastuzumabinhibitsthe
ErbB2 cardioprotective pathways during a vulnerable period
afteranthracyclineinjury,theanthracyclinedamagecouldbe
augmented, resulting in increased cell death [2].
Overall, these results suggest that ErbB2 inhibition result
inmitochondrialapoptoticsignalingincardiomyocyteslead-
ing to increased cell loss in the heart. Therefore, up-regu-
lation of the cardiac neuregulin/ErbB2 pathway may be one
strategy to limit myocardial anthracycline injury. Experi-
mental work on both animals and humans has demonstrated
that exercise is a potent activator of neuregulin release with
subsequent activation of ErbB2 activation [98]. The fact that
exercise protects against calcium-induced cardiac mitochon-
drialpermeabilitytransitionandreducescelldeathfollowing
doxorubicin administration could be related to the neureg-
ulin/ErbB2 survival pathway activation [99].
3.7. Lessons from Targeted Chemotherapy. Several novel “tar-
geted” agents have been associated with a small but wor-
risome risk of heart dysfunction [2, 12–14]. These agents
include the tyrosine kinase inhibitors sunitinib, lapatinib,
andimatinib,whicharemembersofagrowingclassoftarget-
ed chemotherapy agents. Clues as to the nature of the
cardiotoxicity due to these agents are beginning to emerge
that point to the mitochondria. To date, the only approv-
ed kinase inhibitor that is clearly associated with clinical car-
diotoxicity is sunitinib, whereas the extent of imatinib-in-
duced cardiotoxicity is still under scrutiny [12].
On-target cardiac toxicity is inherent to kinase inhibition
and quickly becomes apparent since many of the pathways
that regulate cancer cell survival also regulate essential pro-
cesses in cardiomyocytes, including contractile function and
survival [14, 17]. The ATP binding pocket represents the key
region of the kinase targeted by most inhibitors. Conserva-
tion of that ATP binding pocket among kinases means that
inhibitors can also inhibit unintended kinases, and if any
of these kinases serve important functions in the heart, oﬀ-
target cardiotoxicity can occur. An additional issue is that
targeting of kinases will achieve entire pathway targeting.
For example, the inhibition of multiple components of the
Pi3kinase/Akt pathway is a viable strategy for cancers, but
this pathway also maintains cardiomyocyte homeostasis and
protectscardiomyocytes fromdeath[100].Eventually,kinase
inhibitors could mediate toxicity through the inhibition of
non-kinase targets, such an enzyme requiring ATP to per-
form its function [12, 13].
To illustrate the complexities inherent in identifying me-
chanisms of kinase inhibitor-induced cardiac toxicity, suni-8 Biochemistry Research International
tinib-induced cardiac injury will be discussed. Cardiac dys-
function was ﬁrst related to systemic hypertension secondary
to VEGFR2 and PDGFRbeta inhibition by sunitinib [101].
As several patients developed cardiotoxicity in absence of
hypertension, additional mechanisms were explored. In
this study, endomyocardial biopsy samples from two pa-
tients who presented with profound sunitinib-induced heart
failure were obtained. Abnormal histopathological changes
included marked mitochondrial swelling, which could indi-
cate mPTP and energetic failure [101, 102]. In cultured
cardiomyocytes, the same mitochondrial abnormalities were
observed and were associated with apoptotic cell death [101,
102]. Studies in cardiomyocytes have conﬁrmed that energy
compromise was involved in sunitinib-induced cardiac tox-
icity but surprisingly was not associated with activation of
AMP kinase, the master fuel control of the cell [102]. Lack
of response to this energy loss was the result of direct in-
hibition of AMP kinase by sunitinib, so-called oﬀ-target
toxicity.AMPkinaseinhibitionhasalsobeenreportediniso-
lated heart exposed to doxorubicin [73], whereas recent
studies demonstrated that AMPK gene expression and en-
zyme activities were acutely increased [71]. These results
are important since AMPK is implicated in many survival
pathways, including Pi3k/Akt/mTOR axis [103].
Likewise,imatinib causesamodestbutconsistentdecline
in left ventricular function, which was associated with loss
of myocardial mass and increased cell death [104]. Studies
in cardiomyocytes showed that imatinib leads to signiﬁ-
cant mitochondrial dysfunction with mitochondria swelling,
mitochondrial membrane potential collapse followed by
cytochrome c release and energetic failure [15, 104]. This
processwasassociatedwithacelldeaththathasthebiochem-
icalfeaturesofapoptosisandthemorphologicalaspectofcell
necrosis. Mitochondria isolated from hearts of mice treated
with imatinib showed enhanced calcium-induced swelling
and mitochondrial permeability transition mPTP. As is the
case with trastuzumab, mitochondrial dysfunction plays a
central role in the cardiotoxic response to imatinib, but the
mechanism seems to be the induction of endoplasmic retic-
ulum ER stress by the drug [15, 104]. ER stress in response
to imatinib exposition has been related to the downstream
activation of the c-Jun N-terminal kinase (JNK) family of
stress MAPKs [105]. Similarly, ER stress-mediated apopto-
tic pathway has also been reported to mediate cardiac cell
death induced by doxorubicin [20]. In this case, caspase 12,
which resides in the ER, is an essential caspase to initiate ER-
mediated apoptosis that is activated in doxorubicin-treated
hearts [106].
The Pi3k/Akt/mTOR pathway more than any other epit-
omizes the similarity between cancer cell signaling and sur-
vival signaling in cardiac cells [54]. The cautionary note is
that Pi3k/Akt/mTOR pathway is also critical for cardiomy-
ocyte integrity and survival. Hence, inhibition of multiple
components of the pathway would jeopardize cardiomyocyte
integrity and survival [100]. Conversely, activation of this
signaling cascade, together with other Akt-activated mole-
cules(suchasGSK-3β,mTORand p70S6kinase),elicitspro-
survival and cardiovascular protective eﬀects, which are
mediated by inhibition of opening of the mPTP [62].
4. Conclusion
Cardiac dysfunction is the most severe side eﬀects of anthra-
cycline treatment. The major mechanism of anthracycline
damage involves the generation of reactive oxygen species
ROSbyiron-anthracyclinecomplexes,leadingtolipidperox-
idation and membrane damage. In mitochondria, ROS and
calcium overload lead to mitochondrial permeability transi-
tion pore opening (mPTP), which is associated with the
release of cytochrome c (cyt c) from mitochondria into cyto-
plasm and cell death. Cardiac myocyte loss following acti-
vation of both apoptotic and necrotic pathways provide an
attractive explanation for anthracycline-induced cardiotox-
icity. There is evidence that the stressed cardiac myocyte
survival may rely on both growth and survival pathways that
are altered in the anthracycline-exposed myocardium. Acti-
vation of ErbB2 and Pi3k/Akt/mTOR pathways represents a
major adaptative mechanism for cardioprotection, which are
altered by anthracyclines. The delicate balance between pro-
and antiapoptosis signaling that relies on kinase-regulated
pathways creates a cause for concern when one attempts to
use anticancer molecules, that is, targeted therapies that can
impair the coordinated function of this kinase network.
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